Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment
暂无分享,去创建一个
J. Douketis | W. Ageno | A. Iorio | A. Tosetto | S. Testa | N. Key | M. Marietta | M. Aguilar | M. Crowther | D. Imberti | G. Finazzi | D. Garcia | R. Sarode | W. Lim | D. Prisco | A. Iorio
[1] M. Crowther,et al. Suboptimal effect of a three‐factor prothrombin complex concentrate (Profilnine‐SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose , 2009, Transfusion.
[2] S. Iliceto,et al. Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases , 2009, Journal of Thrombosis and Thrombolysis.
[3] T. Scalea,et al. Low-dose recombinant factor VIIa for trauma patients with coagulopathy. , 2008, Injury.
[4] W. Ageno,et al. Thromboembolic Consequences of Subtherapeutic Anticoagulation in Patients Stabilized on Warfarin Therapy: The Low INR Study , 2008, Pharmacotherapy.
[5] Mark Crowther,et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[6] G. Guyatt,et al. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[7] T. Scalea,et al. Recombinant factor VIIa for warfarin-associated intracranial bleeding. , 2008, Journal of clinical anesthesia.
[8] R. Beyth,et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[9] D. Singer,et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[10] S Bryan,et al. An international multicenter randomized study of computer‐assisted oral anticoagulant dosage vs. medical staff dosage , 2008, Journal of thrombosis and haemostasis : JTH.
[11] J. Douketis,et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[12] M. Crowther,et al. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. , 2008, Blood.
[13] S. Knaub,et al. Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial , 2008, Journal of thrombosis and haemostasis : JTH.
[14] T. Scalea,et al. Recombinant factor VIIa: decreasing time to intervention in coagulopathic patients with severe traumatic brain injury. , 2008, The Journal of trauma.
[15] Y. Caraco,et al. CYP2C9 Genotype‐guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study , 2008, Clinical pharmacology and therapeutics.
[16] C. Leissinger,et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature , 2008, American journal of hematology.
[17] Marc S. Williams,et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin , 2008, Genetics in Medicine.
[18] A. Wu,et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. , 2008, Pharmacogenomics.
[19] S. Lévy,et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial , 2008, The Lancet.
[20] E. Hylek,et al. Risk of thromboembolism with short-term interruption of warfarin therapy. , 2008, Archives of internal medicine.
[21] Candice L. Garwood,et al. Quality of Anticoagulation Care in Patients Discharged from a Pharmacist‐Managed Anticoagulation Clinic After Stabilization of Warfarin Therapy , 2008, Pharmacotherapy.
[22] Kenichi A. Tanaka,et al. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. , 2008, Thrombosis research.
[23] A. Wittkowsky. Dietary supplements, herbs and oral anticoagulants: the nature of the evidence , 2008, Journal of Thrombosis and Thrombolysis.
[24] B. Horne,et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.
[25] J. Freedman,et al. Coagulopathic patients with traumatic intracranial bleeding: defining the role of recombinant factor VIIa. , 2007, The Journal of trauma.
[26] F. Rosendaal,et al. Daily vitamin K supplementation improves anticoagulant stability , 2007, Journal of thrombosis and haemostasis : JTH.
[27] P. Mannucci,et al. Prevention and treatment of major blood loss. , 2007, The New England journal of medicine.
[28] G. Lip,et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.
[29] Kristine M. Thompson,et al. Advances in the care of patients with intracerebral hemorrhage. , 2007, Mayo Clinic proceedings.
[30] D. Wysowski,et al. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. , 2007, Archives of internal medicine.
[31] F. Kamali,et al. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. , 2007, Blood.
[32] Gregory W Albers,et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. , 2007, Archives of internal medicine.
[33] J. Douketis,et al. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. , 2007, Archives of internal medicine.
[34] J. Saltzman,et al. Impact of Anticoagulation on Rebleeding Following Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Hemorrhage , 2006, The American Journal of Gastroenterology.
[35] P. Mannucci,et al. Drug therapy: Prevention and treatment of major blood loss , 2007 .
[36] J Ingerslev,et al. Use of recombinant factor VIIa for emergency reversal of anticoagulation. , 2007, Journal of postgraduate medicine.
[37] J. Caro,et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM) , 2007, Journal of Thrombosis and Thrombolysis.
[38] S. Connolly,et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. , 2006, American heart journal.
[39] M. Hartmann,et al. Hematoma Growth and Outcome in Treated Neurocritical Care Patients With Intracerebral Hemorrhage Related to Oral Anticoagulant Therapy: Comparison of Acute Treatment Strategies Using Vitamin K, Fresh Frozen Plasma, and Prothrombin Complex Concentrates , 2006, Stroke.
[40] E. Nutescu,et al. Warfarin and its interactions with foods, herbs and other dietary supplements , 2006, Expert opinion on drug safety.
[41] J. Dwyer,et al. Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices. , 2006, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.
[42] R. Perera,et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis , 2006, The Lancet.
[43] H G Watson,et al. Guidelines on oral anticoagulation (warfarin): third edition – 2005 update , 2006, British journal of haematology.
[44] M. Braun,et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. , 2006, JAMA.
[45] Eric E. Smith,et al. Timing of Fresh Frozen Plasma Administration and Rapid Correction of Coagulopathy in Warfarin-Related Intracerebral Hemorrhage , 2006, Stroke.
[46] L. Morgan,et al. Low‐Dose Vitamin K to Augment Anticoagulation Control , 2005, Pharmacotherapy.
[47] B. Roitberg,et al. Human Recombinant Factor VII for Emergency Reversal of Coagulopathy in Neurosurgical Patients: A Retrospective Comparative Study , 2005, Neurosurgery.
[48] Peter Wood,et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.
[49] M. Caldwell,et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. , 2005, Clinical medicine & research.
[50] D. Tregouet,et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. , 2005, Blood.
[51] Mark Crowther,et al. Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.
[52] D. Witt,et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. , 2005, Chest.
[53] G. Marchetti,et al. Risks factors for highly unstable response to oral anticoagulation: a case‐control study , 2005, British journal of haematology.
[54] H. Büller,et al. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review , 2005, Critical care medicine.
[55] Howard L McLeod,et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype , 2005, Thrombosis and Haemostasis.
[56] A David Mendelow,et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial , 2005, The Lancet.
[57] D. Brody,et al. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage , 2005, Neurocritical care.
[58] H. Halkin,et al. Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients , 2004, Thrombosis and Haemostasis.
[59] A. Salvador,et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. , 2004, Journal of the American College of Cardiology.
[60] E. Rimon,et al. Safety of anticoagulation therapy in well-informed older patients. , 2004, Archives of internal medicine.
[61] James O'Connor,et al. Factor VIIa for correction of traumatic coagulopathy. , 2004, The Journal of trauma.
[62] S. Greenberg,et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage , 2004, Neurology.
[63] J. Hirsh,et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[64] A. Barkun,et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic Hemostasis and Proton Pump Inhibition are Associated with Improved Outcomes in a Real-Life Setting , 2004, American Journal of Gastroenterology.
[65] M. Pirmohamed,et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.
[66] Daniel Kurnik,et al. Complex Drug-Drug-Disease Interactions Between Amiodarone, Warfarin, and the Thyroid Gland , 2004, Medicine.
[67] D. Witt,et al. A Retrospective Evaluation of the Management of Excessive Anticoagulation in an Established Clinical Pharmacy Anticoagulation Service Compared to Traditional Care , 2003, Journal of Thrombosis and Thrombolysis.
[68] J. Sung,et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. , 2004, Gastrointestinal endoscopy.
[69] M. Crowther,et al. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. , 2004, Thrombosis research.
[70] D. Horstkotte,et al. Optimal Frequency of Patient Monitoring and Intensity of Oral Anticoagulation Therapy in Valvular Heart Disease , 2004, Journal of Thrombosis and Thrombolysis.
[71] H. Halkin,et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. , 2003, Archives of internal medicine.
[72] F. Rosendaal,et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon , 2003, Thrombosis and Haemostasis.
[73] B. Thompson,et al. Recombinant Activated Factor VII for the Rapid Correction of Coagulopathy in Nonhemophilic Neurosurgical Patients , 2003, Neurosurgery.
[74] H. Halkin,et al. Impact of pre-treatment INR level on the effect of intravenous low dose vitamin K in patients with excessive anticoagulation , 2003, Thrombosis and Haemostasis.
[75] É. Pautas,et al. [Excess antivitamin K in elderly hospitalised patients aged over 70. A one-year prospective survey]. , 2003, Presse medicale.
[76] K. Khair,et al. The use of recombinant factor VIIa in children with inherited platelet function disorders , 2003, British journal of haematology.
[77] M. Tarantino,et al. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. , 2003, Journal of neurosurgery.
[78] H. Naritomi,et al. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. , 2003, Thrombosis and haemostasis.
[79] J. Douketis,et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin k in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial☆ , 2003 .
[80] R. Abbate,et al. Safety and effectiveness of low dose oral vitamin K1 administration in asymptomatic out-patients on warfarin or acenocoumarol with excessive anticoagulation. , 2003, Haematologica.
[81] K. Salame,et al. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. , 2002, Medical science monitor : international medical journal of experimental and clinical research.
[82] C. Wilcox,et al. Diagnostic Yield and Clinical Implications of Push Enteroscopy: Results From a Nonspecialized Center , 2002, Journal of clinical gastroenterology.
[83] C. Sanoski,et al. Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. , 2002, Chest.
[84] B. Norrving,et al. Management and Prognostic Features of Intracerebral Hemorrhage During Anticoagulant Therapy: A Swedish Multicenter Study , 2001, Stroke.
[85] A. Mallet,et al. Anticoagulant (Fluindione)-Aspirin Combination in Patients with High-Risk Atrial Fibrillation , 2001, Cerebrovascular Diseases.
[86] S. Skates,et al. Clinical Predictors of Prolonged Delay in Return of the International Normalized Ratio to within the Therapeutic Range after Excessive Anticoagulation with Warfarin , 2001, Annals of Internal Medicine.
[87] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[88] M. Santarelli,et al. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[89] M. Moia,et al. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). , 2001, Haematologica.
[90] J. Douketis,et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial , 2000, The Lancet.
[91] M. Margaglione,et al. Genetic Modulation of Oral Anticoagulation with Warfarin , 2000, Thrombosis and Haemostasis.
[92] D. Witt,et al. Randomized, Placebo‐Controlled Trial of Oral Phytonadione for Excessive Anticoagulation , 2000, Pharmacotherapy.
[93] R. Kumar,et al. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. , 1999, Archives of internal medicine.
[94] A. Schmaier,et al. Use of factor IX complex in warfarin-related intracranial hemorrhage. , 1999, Neurosurgery.
[95] P. Petersen,et al. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. , 1999, Archives of internal medicine.
[96] T. Baglin,et al. Analysis of risk factors for over‐anticoagulation in patients receiving long‐term warfarin , 1998, British journal of haematology.
[97] M. Brigden,et al. Audit of the frequency and clinical response to excessive oral anticoagulation in an out‐patient population , 1998, American journal of hematology.
[98] R. Beyth,et al. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. , 1998, The American journal of medicine.
[99] G. Palareti,et al. A Guide to Oral Anticoagulant Therapy , 1998, Pathophysiology of Haemostasis and Thrombosis.
[100] D. Malone,et al. Evaluation of excessive anticoagulation in a group model health maintenance organization. , 1998, Archives of internal medicine.
[101] G. Guyatt,et al. Grades of recommendation for antithrombotic agents. , 1998, Chest.
[102] F. Rosendaal,et al. Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy , 1997, Thrombosis and Haemostasis.
[103] S. Booth,et al. Dietary Vitamin and Stability of Oral Anticoagulation: Proposal of a Diet with Constant Vitamin K1 Content , 1997, Thrombosis and Haemostasis.
[104] W. J. Hamilton,et al. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.
[105] J. Glover,et al. Conservative treatment of overanticoagulated patients. , 1995, Chest.
[106] J. E. Harris,et al. Interaction of dietary factors with oral anticoagulants: review and applications. , 1995, Journal of the American Dietetic Association.
[107] E. Hylek,et al. Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.
[108] B. Martin,et al. Effect of drug interactions on outcomes of patients receiving warfarin or theophylline. , 1994, American journal of hospital pharmacy.
[109] B. Norrving,et al. Emergency Reversal of Anticoagulation After Intracerebral Hemorrhage , 1992, Stroke.
[110] M. Gibaldi,et al. The mechanism of the interaction between amiodarone and warfarin in humans , 1992, Clinical pharmacology and therapeutics.
[111] G. Clark,et al. Evaluation of Factors Associated with Stability of Anticoagulation Therapy , 1989, Pharmacotherapy.
[112] N. Tabibian. Acute gastrointestinal bleeding in anticoagulated patients: a prospective evaluation. , 1989, The American journal of gastroenterology.
[113] C. Wilcox,et al. Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy. , 1988, The American journal of medicine.
[114] Silvia G. Priori,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for PRAC , 2006 .